Form 4 for TRDA Entrada Therapeutics, Inc.

Accepted 2023-09-06 00:00:00 ET · period of report 2023-09-01 · accession 0001689375-23-000063 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2023-09-06	2023-09-05	TRDA	Sethuraman Natarajan	CSO	F - Tax	$14.46	-449	167.2K	-0.3%	-$6,493
D	2023-09-06	2023-09-01	TRDA	Sethuraman Natarajan	CSO	A - Grant	$0.00	+14.2K	167.6K	+9%	$0
D	2023-09-06	2023-09-01	TRDA	Sethuraman Natarajan	CSO	A - Grant	$0.00	+21.5K	21.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-09-05	F	D	449	$14.46	167,198	D	—	—	(F2) This sale represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of previously granted RSUs.
2	Common	Common Stock	2023-09-01	A	A	14,200	$0.00	167,647	D	—	—	(F1) Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on September 1, 2024; (ii) 25% on September 1, 2025; (iii) 25% on September 1, 2026 and (iv) the remaining 25% on September 1, 2027, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date.
3	Derivative	Stock Option (Right to Buy)	2023-09-01	A	A	21,500	$0.00	21,500	D	$15.41 · — to 2033-09-01	21,500 Common Stock	(F3) 25% of the option shares shall vest and become exercisable on September 1, 2024, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on September 1, 2027.